Reduced Intensity Myeloablative Total Body Irradiation and Thymoglobulin Followed by Allogeneic Peripheral Blood Stem Cell Transplantation

Trial Profile

Reduced Intensity Myeloablative Total Body Irradiation and Thymoglobulin Followed by Allogeneic Peripheral Blood Stem Cell Transplantation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2017

At a glance

  • Drugs Antithymocyte globulin (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Oct 2015 Planned End Date changed from 1 Jul 2016 to 1 Sep 2020 as reported by ClinicalTrials.gov record.
    • 23 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 23 Jan 2013 Planned End Date changed from 1 Jul 2013 to 1 Jul 2016 as reported ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top